Drug Development
Phase II trial with Imvamune in HIV infected patients initiated
Published in AIDS Weekly, August 15th, 2005
The trial involves 150 volunteers and is being conducted at five sites in the United States. This is Bavarian Nordic's second clinical study to evaluate the safety of Imvamune in HIV infected patients and are the only studies evaluating MVA as a safe smallpox vaccine in this population of people, which are contradicted to traditional smallpox vaccines.
Recently, Bavarian Nordic also completed enrollment and vaccination in a phase I clinical study with subjects suffering from atopic dermatitis, another population of people...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-08-15)
More Articles from AIDS Weekly
- HIV-1-Associated Dementia
HIV dementia related to changes in molecular factors involved in infection - HIV/AIDS Drug Development
Peptides derived from HIV-1 RT are inhibitors of the viral integrase - HIV/AIDS Research
HAART suppresses viral load in macaques infected with RT-SHIV - HIV/Tuberculosis Coinfection
Risk of resistance in HIV/TB coinfection depends on rifampin dosing schedule - AIDS-Related Emphysema
AIDS-related emphysema partly due to direct alveolar macrophage HIV-1 infection - Amyotrophic Lateral Sclerosis
FDA wants more information about planned phase II clinical trial for ALS - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
